Protagonist Therapeutics Inc (PTGX) Stock AnalysisPTGXProtagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Protagonist Therapeutics Inc is a good buy right now due to its recent strong financial performance, including a profit of $162.8 million in Q2 2026, and a current price of $143.73, which is below the analyst price target range of $170 to $190. The RSI is at 63.33, indicating bullish momentum, while the stock has shown a year-to-date change of +64.87%. However, the main risk is the high insider selling activity, which has increased by 7175.14% recently, suggesting potential concerns among insiders.

4 analysts cover PTGX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 94.54.